Recent Investment Analysts’ Ratings Updates for Solid Biosciences (SLDB)

Several brokerages have updated their recommendations and price targets on shares of Solid Biosciences (NASDAQ: SLDB) in the last few weeks:

• 9/16/2026 – Solid Biosciences is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $18.00 price target on the stock.
• 9/16/2026 – Solid Biosciences is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $18.00 price target on the stock.
• 9/14/2026 – Solid Biosciences was given a new $25.00 price target by Loop Capital.
• 9/14/2026 – Solid Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
• 8/27/2026 – Solid Biosciences had its price target raised by Cantor Fitzgerald from $16.00 to $26.00. They now have an “overweight” rating on the stock.
• 8/21/2026 – Solid Biosciences had its price target raised by Truist Financial Corporation from $16.00 to $20.00. They now have a “buy” rating on the stock.

Solid Biosciences Inc (NASDAQ:SLDB) is a biotechnology company developing genetic medicines for neuromuscular and cardiac diseases. The company combines gene therapy, genetic medicine and manufacturing technologies to design treatments intended to address the underlying causes of serious inherited disorders.

Solid’s lead program is SGT-003, an investigational gene therapy being developed for Duchenne muscular dystrophy, a progressive genetic disease that causes muscle degeneration. The company is also advancing SGT-501, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, a rare inherited heart condition.